Figure 6
From: Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development
Melanoma tumor morphology is modified by vemurafenib treatment. (A) Hematoxylin and eosin staining of WM983A melanoma model revealed a proliferative nodule morphology whereas (B) the WM983B model showed a more invasive morphology. (C) Macroscopic aspect of non-treated WM983B model with dense tumors and (D) corresponding histological appearance after hematoxylin and eosin staining. (E) Macroscopic aspect of WM983B model treated with 5 µM vemurafenib for 12 days showed tumor pigmentation, which is also visible on (F) hematoxylin and eosin stained tissue sections of the same model. Results are representative of two independent experiments, performed in triplicate. Scale bars: (A,B) 100 µm, (C,E) 2 mm, (D,F) 20 µm.
